Clostridioides (previously clostridium) difficile is an inescapable problem within the critical care arena. This may arise as a nosocomial complication, in which case it is usually diagnosed early and treated successfully. It may also be the primary cause of admission to the ICU, in which case it is generally more severe.
-
The IBCC chapter is located here.
- The podcast & comments are below.
Follow us on iTunes![](https://i0.wp.com/emcrit.org/wp-content/uploads/2016/11/apps.40518.14127333176902609.7be7b901-15fe-4c27-863c-7c0dbfc26c5c.5c278f58-912b-4af9-88f8-a65fff2da477.jpg?resize=100%2C100)
The Podcast Episode
Want to Download the Episode?
Right Click Here and Choose Save-As
Latest posts by Josh Farkas (see all)
- PulmCrit Wee: Rational selection of infusion rate based on loading dose - June 25, 2024
- PulmCrit: PPIs are safe and effective for GI prophylaxis… the end. - June 18, 2024
- PulmCrit: Bilevel Sequence Intubation (BSI) – The new standard - June 17, 2024
Opinion on PPI / H2 blocker use for C. Diff patients in ICU?
the PEPTIC trial showed that PPIs don’t actually increase the rate of C. diff.
PPIs have been correlated with lots of bad things since they are often utilized by multimorbid patients. I don’t think PPI-vs-H2 blocker actually affects C. Diff rates.